Skip to content
Screener

Charles River Laboratories CRL Q2 2026 earnings

Reported August 5, 2026 · Before market open

Revenue$1.0BBeat by $23.5M
EPS$3.02Beat by $0.25
Revenue estimate$980.5M
EPS estimate$2.77
“We made excellent progress in the second quarter on the execution of our Pathway to Purpose strategy. We are actively evaluating opportunities to modernize the Company and drive greater efficiency, to strengthen our leading drug development portfolio centered on regulated testing, and to further enhance our growth profile. We are focused on continuing to move forward on achieving our strategic initiatives and financial goals, which will strengthen our foundation and underpin our future success.”
Birgit Girshick

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$958.5M
EPS estimate$2.96

Financials

Q2 2026

Income statement

See full
Revenue$1.0B-2.7%
Operating income$119.9M+19.7%
Net income-$1.5M-103%
EPS (diluted)-$0.03-103%

Balance sheet

See full
Cash & equivalents$240.6M+30.2%
Total debt$3.0B+8.1%
Total equity$2.8B-15.3%
Total assets$7.5B-0.4%

Cash flow

See full
Operating cash flow$179.7M-12.2%
CapEx$31.1M-11.9%
Free cash flow$148.6M-12.2%

Valuation & ratios

Valuation

as of 08/27/26
See full
Market cap$14.09B+75.8%
Enterprise value$16.89B+58.7%
P/S3.5×+1.5×

Profitability

See full
Net margin-6%—
FCF margin9.3%-5.1pp

Returns & leverage

See full
Return on equity-7.7%—
Debt / equity1.1×+0.2×
Current ratio1.3×0.0×

Segments

By segment

See full
DSA$606.5M-1.9%
RMS$209.5M-1.8%
Manufacturing$188.1M-6.3%

By geography

See full
Europe$263.1M-6.7%
Asia Pacific$60.5M+11.0%
Other$13.1M+27.0%

By product

See full
Cost of services provided (excluding amortization of intangible assets)$808.3M-3.9%

FAQ

When did Charles River Laboratories report Q2 2026 earnings?
Charles River Laboratories (CRL) reported Q2 2026 earnings on August 5, 2026 before market open.
What were Charles River Laboratories's Q2 2026 revenue and EPS?
Charles River Laboratories reported revenue of $1.0B and eps of $3.02 for Q2 2026.
Did Charles River Laboratories beat estimates in Q2 2026?
Revenue beat the consensus estimate of $980.5M by $23.5M. EPS beat the consensus estimate of $2.77 by $0.25.
How did Charles River Laboratories's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 2.7% from $1.0B a year earlier and eps declined 3.2% from $3.12.
Where can I find Charles River Laboratories's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001100682-26-000115) and the 10-Q periodic report (0001100682-26-000118) directly on SEC EDGAR. The filing index links above go to sec.gov.